JP2009256388A5 - - Google Patents

Download PDF

Info

Publication number
JP2009256388A5
JP2009256388A5 JP2009186660A JP2009186660A JP2009256388A5 JP 2009256388 A5 JP2009256388 A5 JP 2009256388A5 JP 2009186660 A JP2009186660 A JP 2009186660A JP 2009186660 A JP2009186660 A JP 2009186660A JP 2009256388 A5 JP2009256388 A5 JP 2009256388A5
Authority
JP
Japan
Prior art keywords
binding
hsp
binds
moiety
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009186660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009256388A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009256388A publication Critical patent/JP2009256388A/ja
Publication of JP2009256388A5 publication Critical patent/JP2009256388A5/ja
Pending legal-status Critical Current

Links

JP2009186660A 1997-05-14 2009-08-11 選択された蛋白質を分解する方法および複合化合物 Pending JP2009256388A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4645197P 1997-05-14 1997-05-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP54951698A Division JP4903922B2 (ja) 1997-05-14 1998-05-14 選択された蛋白質を分解する複合化合物

Publications (2)

Publication Number Publication Date
JP2009256388A JP2009256388A (ja) 2009-11-05
JP2009256388A5 true JP2009256388A5 (enExample) 2011-06-23

Family

ID=21943529

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54951698A Expired - Fee Related JP4903922B2 (ja) 1997-05-14 1998-05-14 選択された蛋白質を分解する複合化合物
JP2009186660A Pending JP2009256388A (ja) 1997-05-14 2009-08-11 選択された蛋白質を分解する方法および複合化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP54951698A Expired - Fee Related JP4903922B2 (ja) 1997-05-14 1998-05-14 選択された蛋白質を分解する複合化合物

Country Status (7)

Country Link
US (1) US6670348B1 (enExample)
EP (1) EP1023315B1 (enExample)
JP (2) JP4903922B2 (enExample)
AT (1) ATE460423T1 (enExample)
CA (1) CA2287387C (enExample)
DE (1) DE69841549D1 (enExample)
WO (1) WO1998051702A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372712B1 (en) * 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
WO2000045805A2 (en) * 1999-02-08 2000-08-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates
WO2000061578A1 (en) * 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1229924A4 (en) 1999-11-19 2004-12-15 Univ Leland Stanford Junior TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2002009696A1 (en) * 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
WO2002094196A2 (en) 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US7465718B2 (en) 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7230139B2 (en) 2002-12-05 2007-06-12 Gemin X Biotechnologies Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
ES2432747T3 (es) 2003-06-27 2013-12-05 Kyowa Hakko Kirin Co., Ltd. Inhibidores de proteínas de la familia HSP90
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
WO2006044457A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
PE20060608A1 (es) * 2004-10-13 2006-08-22 Wyeth Corp Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
EP1869027A4 (en) 2005-03-30 2010-06-23 Conforma Therapeutics Corp ALKYNYL-PYRROLOPYRIMIDINES AND CORRESPONDING ANALOGS AS HSP90 INHIBITORS
CA2620855A1 (en) * 2005-09-01 2007-08-02 Beth Israel Deaconess Medical Center Wortmannin conjugates and uses thereof
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US8012952B2 (en) * 2007-02-13 2011-09-06 Council Of Scientific & Industrial Research Cationic 17 α-substituted-estradiol derivatives useful as anti-cancer agent
JP2010523566A (ja) * 2007-04-05 2010-07-15 ワイス エルエルシー ワートマニン−ラパマイシンコンジュゲートおよびその使用
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
CA2776308C (en) 2009-10-07 2020-01-28 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN103153335A (zh) * 2010-06-30 2013-06-12 布兰代斯大学 小分子靶定的蛋白质降解
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2013170147A1 (en) * 2012-05-11 2013-11-14 Yale University Compounds useful for promoting protein degradation and methods using same
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
HK1245791A1 (zh) 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102616762B1 (ko) 2015-03-18 2023-12-20 아비나스 오퍼레이션스, 인코포레이티드 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
AU2017341723B2 (en) 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
WO2018102725A1 (en) 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN118986983A (zh) 2019-08-26 2024-11-22 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
WO2021077010A1 (en) 2019-10-17 2021-04-22 Arvinas Operations, Inc. Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
PE20231204A1 (es) 2020-05-09 2023-08-17 Arvinas Operations Inc Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022056368A1 (en) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DE3907290A1 (de) * 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand Steroidhormonrezeptoraffine antitumorwirkstoffe
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
GB2278843A (en) * 1993-06-07 1994-12-14 British Tech Group Anti-cancer compounds
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
NZ331062A (en) 1996-10-25 2000-05-26 Kyowa Hakko Kogyo Company Ltd Radicicol derivatives or pharmacologically acceptable salts which show tyrosine kinase inhibition activity and have antitumor effects
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Similar Documents

Publication Publication Date Title
JP2009256388A5 (enExample)
NL301299I2 (nl) Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
PL2265283T3 (pl) Koniugaty aurystatyny lek łącznik
WO2008098788A3 (en) Receptor and antigen targeted prodrug
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
IL211010A (en) Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
PL2411408T3 (pl) Rozpuszczalne przeciwciała "tylko cieżkołańcuchowe"
SG10201405835TA (en) Axl antibodies
PT3248613T (pt) Conjugados de ligante de fármaco e beta-glucuronida
EP2349274A4 (en) FOLAT RECEPTOR BINDING CONJUGATES OF ANTIFOLATES
GB201004799D0 (en) Mobile remittances/payments
IL192944A0 (en) THE USE OF AN ANTI-EpCAM ANTIBODY FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION
ZA201104905B (en) Albumin binding peptide-mediated disease targeting
IL200388A (en) Antibody, antibody hybridoma, antibody-containing conjugate, antibody-containing drug and / or conjugate and their uses
EP2354405A4 (en) FORWARD MOVEMENT MECHANISM OF A MOBILE BODY
PT2155248E (pt) Direcionamento a abcb5 para tratameto do cancro
EP3450459A3 (en) Anti-cdh3 antibodies and uses thereof
ZA201003729B (en) Conjugates of anti-rg-1 antibodies
EP2106442A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
IL205290A0 (en) Novel neurturin conjugates for pharmaceutical use
ZA201002561B (en) Reflective road marker
EP2104732A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
ZA200905063B (en) Cancerous disease modifying antibodies
BRPI0811431A2 (pt) Composição farmacêutica aquosa.